Sub-system
A small-molecule drug is an organic compound of a few dozen atoms, made by chemical synthesis and usually swallowed. It is cheap to manufacture, stable on a shelf, and goes from expensive to nearly free the day its patent expires — and that cliff shapes the entire industry around it.
In one sentence
A small molecule is a low-molecular-weight organic compound, manufactured by chemical synthesis, small enough to be absorbed through the gut and to enter cells and act on targets inside them.
Size is the whole advantage. Being small enough to survive the digestive tract and cross membranes is what allows a tablet, and being able to enter a cell is what allows a drug to act on targets that a large protein circulating in the blood can never reach. No other modality has both properties.
Manufacturing is chemistry rather than biology: a sequence of reactions producing an active ingredient, formulated into a tablet or capsule. Cost per dose is measured in cents at scale, which is why small molecules dominate by volume even as biologics dominate by revenue.
Beyond hitting its target, a molecule has to dissolve, survive the gut and the liver's first pass, reach the tissue where it acts, avoid unrelated targets, and clear at a rate that suits the dosing schedule. Most failures are here rather than in potency, and much of medicinal chemistry is trading a little activity for far better behaviour in the body.
When exclusivity ends, generic manufacturers can prove equivalence with bioequivalence studies rather than new trials, and price falls dramatically within months. That is excellent for patients and it means the revenue from a successful small molecule is a defined window — which is why the industry is organised around a pipeline replacing what is about to expire.
Targeted protein degradation recruits the cell's own disposal machinery to destroy a target rather than merely blocking it, which reaches proteins long considered undruggable. Covalent inhibitors that bond permanently to their target have also returned. Both are small molecules, and both extend what the oldest modality can do.
1 of these is marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
Synthesis is concentrated in a small number of countries, with intermediates concentrated further upstream still.
BiomanufacturingFinding a molecule with the right activity and the right behaviour in the body is the long pole in discovery.
The generic pathway is what produces the price cliff, and its requirements define when it can happen.
Regulatory approvalIdentity, assay and impurity limits are proven instrument by instrument, and a batch without that data cannot be released whatever the chemistry did.
Analytical instrumentsMonographs fix the tests and limits an active ingredient and a finished dose have to meet, and they are what a generic filing is measured against.
Other pages in this map that name Small molecules as something they cannot do without.
What each company supplies at this step, and — where a public figure exists — its share of this specific market — with what that share measures, the period it covers and who published it. Some rows also show the company’s own reported revenue for the segment covering this step, which is a different thing: it says how much this business matters to that company, not how much of the market it holds. Not a ranking and not a recommendation.
Develops and manufactures small-molecule medicines across therapeutic areas.
Develops small-molecule and biologic medicines at scale.
Provides contract research and small-molecule manufacturing services.
Develops and manufactures small-molecule and biologic therapies.
Runs the largest contract manufacturing network, small molecules included, and is where much of the outsourced chemistry actually happens.
Supplies active ingredient and finished-dose manufacturing across European and US sites.
One of the largest active-ingredient makers, and part of why the cost base of generic chemistry sits where it does.
Supplies process chemistry and manufacturing from China, on the same export-exposure question as the larger contract organisations.
Whether targeted protein degradation delivers approved medicines against previously undruggable targets.
Whether active ingredient manufacturing is meaningfully diversified away from its current concentration.
How pricing policy changes the value of the exclusivity window.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer